Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT03809078
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Overview
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
Sponsor
Stanford University
Phase
Phase 2
Contacts
Andrei H Iagaru, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT03809078Eligibility
Inclusion
- Able to provide written consent
- Suspected prostate cancer
- Karnofsky performance status of 50 (or ECOG/WHO equivalent)
- Planned prostate biopsy
Exclusion
- Metallic implants (contraindicated for MRI)
- Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam
Share your feedback
Help us improve your experience